New York, February 16, 2026, 11:21 (EST) — The market has closed.
- UnitedHealth Group ended Friday’s session at $293.19, up 3.1%.
- Presidents’ Day keeps U.S. markets closed, with trading set to pick up again Tuesday.
- The next major variable for managed-care shares: Medicare Advantage rate decisions.
UnitedHealth Group Incorporated shares finished Friday at $293.19, up 3.1%, extending a rebound that capped off a tough January for the insurer. With U.S. markets shuttered Monday for Presidents’ Day, trading will pick back up on Tuesday. (Barron’s)
The pause is significant: the stock’s next move hinges on Washington as much as on quarterly numbers. Eyes are on how the U.S. government decides 2027 Medicare Advantage payments, the program letting private insurers manage Medicare for seniors and people with disabilities.
The Centers for Medicare & Medicaid Services has set a Feb. 25 deadline for feedback on its 2027 Medicare Advantage and Part D “Advance Notice.” The agency plans to issue the final rate announcement by April 6. (CMS)
Friday’s advance wrapped up a three-day rally for UnitedHealth, with the stock up 2.1% on Feb. 11, another 2.0% jump on Feb. 12, and a 3.1% push on Feb. 13. That’s about a 7% gain from where it finished on Feb. 10. (Investing.com)
The stock’s rally follows a steep pullback late last month after the company flagged a revenue drop in 2026, alongside the government’s nearly unchanged 0.09% increase for 2027 Medicare Advantage rates. UnitedHealthcare CEO Tim Noel labeled the move “disappointing,” warning of “very meaningful benefit reductions.” Morningstar’s Julie Utterback didn’t sound too optimistic either: “Investors hoping for a quick turnaround may have to wait longer than hoped.” (Reuters)
UnitedHealth projected full-year 2026 revenue topping $439.0 billion, with adjusted earnings at over $17.75 per share, according to its Jan. 27 earnings release. “We confronted challenges directly and finished 2025 as a much stronger company,” CEO Stephen Hemsley said. (UnitedHealth Group)
Traders now have to decide: is this bounce just a breather after the selloff, or are we looking at the first steps toward a more durable shift as the market waits for real numbers on pricing and medical costs in early 2026? UnitedHealth’s Medicare segment and its Optum unit are right at the heart of that argument.
Peers face similar crosswinds. Shares of Humana and CVS Health have mirrored the swings tied to Medicare Advantage headlines; the group often trades in lockstep when the outlook on reimbursements changes.
Here’s the risk: Should the final Medicare Advantage rate land near the proposed figure and medical utilization remain steady, insurers could respond by cutting benefits, shrinking their coverage areas, or ratcheting up pricing. That would threaten both enrollment growth and margins. Moves like these can also catch lawmakers’ attention—so the volatility doesn’t let up.
Investors will be eyeing UnitedHealth on Tuesday to see if the stock hangs onto Friday’s pop, as the market weighs what’s next in the Medicare Advantage rate process. Comments are due Feb. 25, and the final rate lands April 6.
